Although the primary endpoint for the overall population was not fulfilled, in former smokers with COPD, targeting IL-33 reduced the frequency of exacerbations and improved lung function compared with those in the placebo group [82, 110]. This evidence concerns the gene IL33 and chronic obstructive pulmonary disease.